Company news
Biofrontera Inc. news in 2023
Biofrontera Inc.'s news releases, calls and decks from 2023, newest first.
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 8, 2023
Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10
November 2, 2023
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
October 30, 2023
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)
October 9, 2023
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
October 3, 2023
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
August 28, 2023
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)
August 27, 2023
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 10, 2023
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
August 9, 2023
Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%
July 12, 2023
Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors
July 11, 2023
Biofrontera Inc. Announces 1-for-20 Reverse Stock Split
July 2, 2023
Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.
June 11, 2023
Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT
May 31, 2023
Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer
May 29, 2023
Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects
May 14, 2023
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update
May 11, 2023
Biofrontera Inc. Announces Resignation of CEO
May 11, 2023
Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million
May 10, 2023
Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention
May 8, 2023
Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023
April 27, 2023
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
April 25, 2023
Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce
March 26, 2023
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
March 8, 2023
Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
March 7, 2023
Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023
March 1, 2023
Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
February 21, 2023
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
January 8, 2023
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
January 8, 2023